Chimeric: Media Thread, page-674

Thanks for sharing. pinch. Back in Nov '22, this 3rd Gen CAR-T was still in the lab but hopeful of being progressed into the clinic. And, here we are heading into the clinic with 3 trials investigating CDH17 and ongoing pre-clinical studies into other solid cancers expressing CDH17.






I think Dr Hua states 100% of GI NETs (Gastrointestinal Neuroendocrine Tumors) express CDH17 in his presentation. Does this suggest that CDH17 could be a target expressed on neuroendocrine cells manifesting as tumours elsewhere in the body?

https://www.pennmedicine.org/news/news-releases/2022/march/penn-developed-car-t-cells-suppress-gi-solid-tumor-cells-without-toxicity-to-healthy-tissue

https://www.pennmedicine.org/cancer/types-of-cancer/neuroendocrine-tumors/types-of-neuroendocrine-tumors/gastrointestinal-neuroendocrine-tumors